


## US Measles Mortality Rates (PER 100,000 POPULATION)



Source: Vital Statistics Rates in the United States, 1940–1960




Chart courtesy of Becky Estep

**COMMITTEE TO REVIEW ADVERSE EFFECTS OF VACCINES  
DECEMBER 2009 WORKING LIST OF ADVERSE EVENTS TO BE CONSIDERED BY THE COMMITTEE**

<b>DTaP/Tetanus Containing Vaccines</b>	<b>Hepatitis A Vaccine</b>	<b>Meningococcal Vaccine</b>	<b>MMR Vaccine</b>
<ul style="list-style-type: none"> <li>• Anaphylaxis or Anaphylactic Shock</li> <li>• Arthropathy (Arthritis, Arthralgia)</li> <li>• Autism*</li> <li>• Autism Spectrum Disorders (ASD)/Pervasive Developmental Disorders (PDD)*</li> <li>• Ataxia</li> <li>• Bell's Palsy</li>   <li>• Chronic, Remitting Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Chronic Inflammatory Disseminated Polyneuropathy</li> <li>▪ Multiple Sclerosis</li> </ul> </li> <li>• Chronic Urticaria</li> <li>• Complex Regional Pain Syndrome</li> <li>• Convulsions:               <ul style="list-style-type: none"> <li>▪ Febrile, Afebrile</li> <li>▪ Infantile Spasms</li> <li>▪ Myoclonic Epilepsy</li> </ul> </li> <li>• Encephalopathy/Encephalitis</li> <li>• Fibromyalgia</li>   <li>• Immune Thrombocytopenic Purpura</li> <li>• Insulin-dependent Diabetes Mellitus</li> <li>• Monophasic Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Acute Disseminating Encephalomyelitis</li> <li>▪ Guillain-Barré Syndrome</li> <li>▪ Transverse Myelitis</li> </ul> </li> <li>• Myocarditis</li> <li>• Opsoclonus Myoclonus Syndrome</li> <li>• Optic Neuritis</li> <li>• Serum Sickness</li> <li>• Sudden Infant Death Syndrome (SIDS)</li> </ul>	<ul style="list-style-type: none"> <li>• Anaphylaxis or Anaphylactic Shock</li>   <li>• Bell's Palsy</li>   <li>• Chronic, Remitting Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Chronic Inflammatory Disseminated Polyneuropathy</li> <li>▪ Multiple Sclerosis</li> </ul> </li>   <li>• Hepatitis (autoimmune)</li>   <li>• Monophasic Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Acute Disseminating Encephalomyelitis</li> <li>▪ Guillain-Barré Syndrome</li> <li>▪ Transverse Myelitis</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Anaphylaxis or Anaphylactic Shock</li>   <li>• Chronic Headaches</li> <li>• Chronic, Remitting Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Chronic Inflammatory Disseminated Polyneuropathy</li> <li>▪ Multiple Sclerosis</li> </ul> </li>   <li>• Encephalopathy/Encephalitis</li>   <li>• Monophasic Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Acute Disseminating Encephalomyelitis</li> <li>▪ Guillain-Barré Syndrome</li> <li>▪ Transverse Myelitis</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Anaphylaxis or Anaphylactic Shock</li> <li>• Arthropathy (Arthritis, Arthralgia)</li> <li>• Autism*</li> <li>• Autism Spectrum Disorders (ASD)/Pervasive Developmental Disorders (PDD)*</li> <li>• Ataxia</li>   <li>• Brachial Neuritis</li> <li>• Chronic Fatigue Syndrome</li>   <li>• Chronic, Remitting Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Chronic Inflammatory Disseminated Polyneuropathy</li> <li>▪ Multiple Sclerosis</li> </ul> </li> <li>• Complex Regional Pain Syndrome</li> <li>• Convulsions:               <ul style="list-style-type: none"> <li>▪ Febrile, Afebrile</li> <li>▪ Infantile Spasms</li> <li>▪ Myoclonic Epilepsy</li> </ul> </li> <li>• Encephalopathy/Encephalitis</li> <li>• Fibromyalgia</li> <li>• Hearing Loss</li> <li>• Hepatitis</li>   <li>• Insulin-dependent Diabetes Mellitus</li> <li>• Monophasic Demyelinating Diseases:               <ul style="list-style-type: none"> <li>▪ Acute Disseminating Encephalomyelitis</li> <li>▪ Guillain-Barré Syndrome</li> <li>▪ Transverse Myelitis</li> </ul> </li> <li>• Opsoclonus Myoclonus Syndrome</li> </ul>

\* "Secondary" autism or autistic features arising from chronic encephalopathy, mitochondrial disorders and/or other underlying disorders will be considered by the Committee. For "Primary" autism, VICEP has asked the IOM to consider the review of the medical literature post *Immunization Safety Review: Vaccines and Autism (2004)* report. In particular, VICEP is interested in the Committee's review on more recent theories of "neuroinflammation" and "hyperarousal/overexcitation of the immune system via multiple simultaneous antigenic stimulation."

# HRSA—National Vaccine Injury Compensation Program Statistics Reports

Statistics—March 5, 2014

## *I. Petitions Filed*

Fiscal Year	Total
FY 1988	24
FY 1989	148
FY 1990	1,492
FY 1991	2,718
FY 1992	189
FY 1993	140
FY 1994	107
FY 1995	180
FY 1996	84
FY 1997	104
FY 1998	120
FY 1999	411
FY 2000	164
FY 2001	216
FY 2002	957
FY 2003	2,592
FY 2004	1,214
FY 2005	735
FY 2006	325
FY 2007	410
FY 2008	417
FY 2009	397
FY 2010	449
FY 2011	386
FY 2012	400
FY 2013	503
FY 2014	218
Total	15,100

## *II. Adjudications*

Fiscal Year	Compensable	Dismissed	Total
FY 1989	9	12	21
FY 1990	100	33	133
FY 1991	141	447	588
FY 1992	166	487	653
FY 1993	125	588	713
FY 1994	162	446	608
FY 1995	160	575	735
FY 1996	162	408	570
FY 1997	189	198	387
FY 1998	144	181	325
FY 1999	98	139	237
FY 2000	125	104	229
FY 2001	86	87	173
FY 2002	104	103	207
FY 2003	56	99	155
FY 2004	62	233	295
FY 2005	60	121	181
FY 2006	69	191	260
FY 2007	83	120	203
FY 2008	147	134	281
FY 2009	134	231	365
FY 2010	181	292	473
FY 2011	261	1,371	1,632
FY 2012	260	2,439	2,699
FY 2013	366	627	993
FY 2014	90	68	158
Totals	3,540	9,734	13,274

### III. Awards Paid

Fiscal Year	Compensated			Dismissed		Interim Fees		Total Outlays
	# of Awards	Petitioners' Award Amount	Attorneys' Fees/Costs Payments	# of Payments to Attorneys	Attorneys' Fees/Costs Payments	# of Payments to Attorneys	Attorneys' Fees/Costs Payments	
FY 1989	6	\$1,317,654.78	\$54,107.14	0	\$0.00	0	\$0.00	\$1,371,761.92
FY 1990	88	\$53,252,510.46	\$1,379,005.79	4	\$57,699.48	0	\$0.00	\$54,689,215.73
FY 1991	114	\$95,980,493.16	\$2,364,758.91	30	\$496,809.21	0	\$0.00	\$98,842,061.28
FY 1992	130	\$94,538,071.30	\$3,001,927.97	118	\$1,212,677.14	0	\$0.00	\$98,752,676.41
FY 1993	162	\$119,693,267.87	\$3,262,453.06	272	\$2,447,273.05	0	\$0.00	\$125,402,993.98
FY 1994	158	\$98,151,900.08	\$3,571,179.67	335	\$3,166,527.38	0	\$0.00	\$104,889,607.13
FY 1995	169	\$104,085,265.72	\$3,652,770.57	221	\$2,276,136.32	0	\$0.00	\$110,014,172.61
FY 1996	163	\$100,425,325.22	\$3,096,231.96	216	\$2,364,122.71	0	\$0.00	\$105,885,679.89
FY 1997	179	\$113,620,171.68	\$3,898,284.77	142	\$1,879,418.14	0	\$0.00	\$119,397,874.59
FY 1998	165	\$127,546,009.19	\$4,002,278.55	121	\$1,938,065.50	0	\$0.00	\$133,484,353.24
FY 1999	96	\$95,917,680.51	\$2,799,910.85	117	\$2,306,957.40	0	\$0.00	\$101,024,548.76
FY 2000	136	\$125,945,195.64	\$4,112,369.02	80	\$1,724,451.08	0	\$0.00	\$131,782,015.74
FY 2001	97	\$105,878,632.57	\$3,373,865.88	57	\$2,066,224.67	0	\$0.00	\$111,318,723.12

Fiscal Year	Compensated			Dismissed		Interim Fees		Total Outlays
	# of Awards	Petitioners' Award Amount	Attorneys' Fees/Costs Payments	# of Payments to Attorneys	Attorneys' Fees/Costs Payments	# of Payments to Attorneys	Attorneys' Fees/Costs Payments	
FY 2002	80	\$59,799,604.39	\$2,653,598.89	50	\$656,244.79	0	\$0.00	\$63,109,448.07
FY 2003	65	\$82,816,240.07	\$3,147,755.12	69	\$1,545,654.87	0	\$0.00	\$87,509,650.08
FY 2004	57	\$61,933,764.20	\$3,079,328.55	69	\$1,198,615.96	0	\$0.00	\$66,211,708.71
FY 2005	64	\$55,065,797.01	\$2,694,664.03	71	\$1,790,587.29	0	\$0.00	\$59,551,048.33
FY 2006	68	\$48,746,162.74	\$2,441,199.02	54	\$1,353,632.61	0	\$0.00	\$52,540,994.37
FY 2007	82	\$91,449,433.89	\$4,034,154.37	61	\$1,692,020.25	0	\$0.00	\$97,175,608.51
FY 2008	141	\$75,716,552.06	\$5,270,237.04	72	\$2,432,847.05	2	\$117,265.31	\$83,536,901.46
FY 2009	131	\$74,142,490.58	\$5,404,711.98	36	\$1,557,139.53	28	\$4,241,362.55	\$85,345,704.64
FY 2010	173	\$179,387,341.30	\$5,961,744.40	56	\$1,886,239.95	22	\$1,978,803.88	\$189,214,129.53
FY 2011	251	\$216,319,428.47	\$9,736,216.87	402	\$5,425,243.19	28	\$2,001,770.91	\$233,482,659.44
FY 2012	250	\$163,511,998.82	\$9,104,488.60	1,017	\$8,621,182.32	37	\$5,420,257.99	\$186,657,927.73
FY 2013	375	\$254,666,326.70	\$13,250,679.53	704	\$7,052,778.84	50	\$1,454,851.74	\$276,424,636.81
FY 2014	135	\$71,315,951.56	\$3,875,092.47	388	\$3,844,409.26	17	\$1,275,262.25	\$80,310,705.54
<b>Total</b>	<b>3,535</b>	<b>\$2,671,223,269.97</b>	<b>\$109,305,515.01</b>	<b>4,761</b>	<b>\$60,908,457.99</b>	<b>184</b>	<b>\$16,489,564.63</b>	<b>\$2,857,926,807.60</b>

## *Claims Filed and Compensated or Dismissed by Vaccine, March 5, 2014*

Vaccines Listed in Claims as Reported by Petitioners

Vaccine(s)	Filed			Compensated	Dismissed
	Injury	Death	Total		
DT (diphtheria-tetanus)	69	9	78	24	50
DTaP (diphtheria-tetanus-acellular pertussis)	358	76	434	170	193
DTaP-Hep B-IPV	60	24	84	27	28
DTaP-HIB	7	1	8	4	3
DTaP-IPV-HIB	16	13	29	4	7
DTP (diphtheria-tetanus-whole-cell pertussis)	3,285	696	3,981	1,269	2,704
DTP-HIB	18	8	26	4	20
Hep A-Hep B	14	0	14	8	1
Hep B-HIB	8	0	8	4	3
Hepatitis A (Hep A)	55	2	57	21	16
Hepatitis B (Hep B)	604	53	657	234	354
HIB (Haemophilus influenzae type b)	23	3	26	12	14
HPV (human papillomavirus)	213	11	224	69	69
Influenza (Trivalent)	1,317	73	1,390	698	125
IPV (inactivated polio)	262	14	276	7	267



Vaccine(s)	Filed			Compensated	Dismissed
	Injury	Death	Total		
Measles	143	19	162	55	107
Meningococcal	34	1	35	22	3
MMR (measles-mumps-rubella)	866	57	923	357	489
MMR-varicella	28	1	29	13	6
MR	15	0	15	6	9
Mumps	10	0	10	1	9
Nonqualified	82	9	91	0	85
OPV (oral polio)	280	28	308	158	150
Pertussis	4	3	7	2	5
Pneumococcal conjugate	38	5	43	10	25
Rotavirus	57	1	58	35	16
Rubella	189	4	193	70	123
Td (tetanus-diphtheria)	180	3	183	102	64
Tdap	154	1	155	69	7
Tetanus	89	2	91	39	35
Unspecified	5,410	8	5,419	4	4,728
Varicella	75	7	82	42	20
<b>TOTAL</b>	<b>13,964</b>	<b>1,132</b>	<b>15,096</b>	<b>3,540</b>	<b>9,735</b>

*National Vaccine Injury Compensation Program (VICP) Adjudication Categories by Vaccine for Claims Filed, Calendar Year 2006 to 2013*

Vaccine Alleged by Petitioner	No. of Doses Distributed US CY 2006–CY 2012 (Source: CDC)	Compensable			Compensable Total	Dismissed/Non-Compensable Total	Grand Total
		Concession	Court Decision	Settlement			
DT	592,707	1	0	3	4	3	7
DTaP	68,113,573	10	16	69	95	64	159
DTaP-Hep B-IPV	38,347,667	4	6	18	28	31	59
DTaP-HIB	1,135,474	0	0	0	0	1	1
DTaP-IPV-HIB	46,633,881	0	0	5	5	8	13
DTP	0	0	1	2	3	1	4
Hep A-Hep B	10,405,325	0	0	8	8	0	8
Hep B-HIB	4,621,999	1	1	1	3	1	4
Hepatitis A (Hep A)	110,596,300	1	5	17	23	17	40
Hepatitis B (Hep B)	116,853,062	2	10	34	46	29	75
HIB	70,755,674	0	1	4	5	4	9
HPV	55,168,454	10	0	59	69	73	142
Influenza	809,000,000	18	65	616	699	134	833
IPV	52,439,162	0	0	3	3	2	5

Vaccine Alleged by Petitioner	No. of Doses Distrib- uted US CY 2006–CY 2012 (Source: CDC)	Compensable			Compensable Total	Dismissed/Non- Compensable Total	Grand Total
		Concession	Court Decision	Settlement			
Measles	135,660	0	0	1	1	0	1
Meningococcal	51,173,032	1	1	20	22	3	25
MMR	65,864,745	16	14	48	78	64	142
MMR-varicella	8,073,618	7	0	7	14	7	21
Nonqualified	N/A	0	0	0	0	20	20
OPV	0	1	0	0	1	3	4
Pneumococcal conjugate	123,606,306	0	1	5	6	13	19
Rotavirus	61,336,583	0	2	14	16	5	21
Rubella	422,548	0	1	0	1	0	1
Td	53,009,015	4	5	47	56	15	71
Tdap	133,744,203	6	5	59	70	7	77
Tetanus	3,836,052	2	0	14	16	10	26
Unspecified	N/A	1	0	2	3	538	541
Varicella	82,534,257	3	5	17	25	10	35
<b>GRAND TOTAL</b>	<b>1,968,399,297</b>	<b>88</b>	<b>139</b>	<b>1,073</b>	<b>1,300</b>	<b>1,063</b>	<b>2,363</b>